Daratumumab for Multiple Myeloma
Daratumumab is a CD38-targeting monoclonal antibody administered intravenously at 16 mg/kg or subcutaneously at 1800 mg, indicated for multiple myeloma across various treatment lines—from newly diagnosed patients (in combination regimens) to heavily pretreated relapsed/refractory disease (as monotherapy after ≥3 prior therapies). 1, 2
Indications
Daratumumab is FDA-approved for multiple clinical scenarios in multiple myeloma:
Newly Diagnosed Multiple Myeloma
- Transplant-eligible patients: Combined with bortezomib, lenalidomide, and dexamethasone (dara-VRd) or with bortezomib, thalidomide, and dexamethasone 3, 2
- Transplant-ineligible patients: Combined with lenalidomide and dexamethasone or bortezomib and dexamethasone 2
Relapsed/Refractory Multiple Myeloma
- After ≥1 prior therapy: Combined with bortezomib and dexamethasone (CASTOR trial showed 83% vs 63% ORR, PFS not reached vs 7.14 months) 4 or with lenalidomide and dexamethasone (POLLUX trial showed 93% vs 76% ORR, PFS not reached vs 18.4 months) 4
- After ≥2 prior therapies: Combined with pomalidomide and dexamethasone (for patients who received lenalidomide and a proteasome inhibitor) 2
- After ≥3 prior therapies: As monotherapy for patients who received a proteasome inhibitor and immunomodulatory agent, or who are double-refractory to both 1, 2
The monotherapy indication showed 29.2% ORR with median response duration of 7.4 months and 65% estimated 1-year overall survival in heavily pretreated patients 1.
Dosing Schedule and Administration
Intravenous Formulation
Subcutaneous Formulation
- Dose: 1800 mg fixed dose 5
- Schedule: Same frequency as IV formulation
- Administration time: 3-5 minutes 5
- Advantages: Significantly shorter administration time, lower infusion-related reaction rates (median first dose <10% vs 50% for IV), lower infusion volume (15 mL vs 500-1000 mL) 5
The subcutaneous formulation achieves similar or greater serum concentrations compared to IV dosing with comparable efficacy and safety 5.
Premedication Requirements
Mandatory premedication before each infusion 2:
- Corticosteroids: Reduce infusion-related reactions
- Antipyretics: Typically acetaminophen
- Antihistamines: Both H1 and H2 blockers
Post-infusion medications are also required 2.
Critical Monitoring Parameters
Before Treatment Initiation
- Type and screen: Must be performed before starting daratumumab, as the drug binds to CD38 on red blood cells, causing false-positive indirect Coombs tests and interfering with blood compatibility testing for up to 6 months after the last dose 3, 2
- Inform blood banks: All transfusion services must be notified that the patient is receiving daratumumab 2
During Treatment
- Complete blood counts: Monitor periodically for neutropenia, thrombocytopenia, and anemia 2
- Infection surveillance: Neutropenic patients require close monitoring for signs of infection 2
- Response assessment considerations: For IgG kappa myeloma patients, daratumumab (an IgG kappa antibody) can produce spurious positive immunofixation results—use mass spectrometry-based assessment or special interference testing to differentiate therapeutic antibody from M-protein 3
Adverse Effects and Management
Infusion-Related Reactions
- Incidence: 42.5% with IV monotherapy (mostly grade 1/2), predominantly during first infusion 1
- Timing: 92% occur only with first infusion 4
- Symptoms: Shortness of breath, cough, throat irritation, runny nose, fever, chills, nausea, vomiting, hypotension, hypertension 2
- Management: Interrupt infusion for any severity; permanently discontinue for anaphylaxis or life-threatening reactions 2
Hematologic Toxicities
- Neutropenia: Common; dose delays may be required for recovery 2
- Thrombocytopenia: 54% in CASTOR trial; monitor and delay dosing as needed 4, 2
- Anemia: 33% in monotherapy studies 1
Infections
- Upper respiratory tract infections: Increased risk, particularly with combination regimens 4
- Pneumonia: Higher risk with daratumumab-based regimens 6
Other Common Adverse Events (≥20%)
Fatigue, peripheral edema, nausea, diarrhea, constipation, cough, pyrexia, dyspnea, peripheral sensory neuropathy 2.
Contraindications
Absolute contraindication: History of severe hypersensitivity to daratumumab or any formulation component 2.
Special Populations and Considerations
Elderly and Frail Patients
Prolonged steroid use can be detrimental in frail patients ≥60 years—reduce dexamethasone to 20 mg weekly and discontinue with treatment response plateau or toxicity 3.
Renal Dysfunction
Not a contraindication to treatment 3.
Pregnancy
Embryo-fetal toxicity: Can cause fetal harm; advise pregnant women of risks and counsel females of reproductive potential to use effective contraception 2.
Clinical Efficacy Highlights
The addition of daratumumab to standard regimens consistently demonstrates:
- 61-70% reduction in risk of progression or death in relapsed/refractory settings 4
- Doubled depth of response (VGPR rates: 59% vs 29% in CASTOR; 76% vs 44% in POLLUX) 4
- Benefit independent of cytogenetic risk groups 4
Common Pitfalls to Avoid
- Failing to type and screen before treatment: This creates delays in emergency transfusions later
- Not informing blood banks: Transfusion services must know about daratumumab therapy
- Misinterpreting immunofixation in IgG kappa patients: The therapeutic antibody can be mistaken for disease progression
- Inadequate premedication: Increases risk of severe infusion reactions
- Continuing full-dose steroids in elderly patients: Taper dexamethasone to 20 mg weekly in frail patients ≥60 years